Could a common vitamin boost immunotherapy for melanoma?
NCT ID NCT06377111
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether taking high-dose vitamin B5 (pantothenic acid) can help standard immunotherapy work better for people with advanced melanoma that cannot be surgically removed. The study includes 12 participants who have not had prior treatment for their advanced cancer. Researchers will measure vitamin B5 levels in the blood and look for signs of immune system changes and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vitamin B5 (pantothenic acid, calcium pantothenate)
What this could lead to
If it works, this could point toward a simple vitamin supplement that helps immunotherapy work better for advanced melanoma.
What could go wrong
This is a very small, early phase 1 trial with only 12 people. It mainly checks if vitamin B5 levels rise in the blood, not whether it actually improves cancer outcomes. Success is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Health Network- Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada